PR Newswire
SAN DIEGO, March 8, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the
ROTH Capital Partners 29th Annual Growth Stock Conference in Dana Point, CA at 10:30 a.m. PT (1:30 p.m. ET) on Tuesday, March 14,
2017.
The presentation will be made available to the public via live audio webcast which can be accessed by visiting the investor
relations section of Aethlon Medical's corporate website at http://www.aethlonmedical.com. The webcast will be available for replay approximately one hour after the
conclusion of the live event.
About Aethlon Medical, Inc.
Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's
natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The
technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including
natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to
improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the
potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and
the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI),
which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including
Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated
as the basis for a blood-based test to identify CTE in living individuals. Additional information can be found online at
www.AethlonMedical.com and www.ExosomeSciences.com. You can also connect with us on Twitter, LinkedIn, Facebook and Google+.
Contacts:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-roth-capital-partners-29th-annual-growth-stock-conference-on-march-14-2017-300419676.html
SOURCE Aethlon Medical, Inc.
